letrozole has been researched along with Low Bone Density in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 9.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 7.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 5.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 3.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Livi, L | 1 |
| Scotti, V | 1 |
| Desideri, I | 1 |
| Saieva, C | 1 |
| Cecchini, S | 1 |
| Francolini, G | 1 |
| Becherini, C | 1 |
| Delli Paoli, C | 1 |
| Visani, L | 1 |
| Salvestrini, V | 1 |
| De Feo, ML | 1 |
| Nori, J | 1 |
| Bernini, M | 1 |
| Sanchez, L | 1 |
| Orzalesi, L | 1 |
| Bianchi, S | 1 |
| Meattini, I | 1 |
| Majithia, N | 1 |
| Atherton, PJ | 2 |
| Lafky, JM | 1 |
| Wagner-Johnston, N | 1 |
| Olson, J | 1 |
| Dakhil, SR | 2 |
| Perez, EA | 2 |
| Loprinzi, CL | 2 |
| Hines, SL | 2 |
| Gibson, K | 1 |
| O'Bryant, CL | 1 |
| Geisler, J | 1 |
| Lønning, PE | 1 |
| Sloan, JA | 1 |
| Johnson, DB | 1 |
| Reddy, PS | 1 |
| Dalton, RJ | 1 |
| Mattar, BI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial[NCT02616744] | Phase 2 | 171 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy[NCT00436917] | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change: BMD values at year 1 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 5.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 10.47 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 8.44 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.49 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.54 |
Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 2.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.94 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.20 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.99 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 11.71 |
Adverse events were assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Grade 1=Mild, Grade 2=Moderate. (NCT00436917)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Arthralgia | Grade 2 Arthralgia | Grade 3 Arthralgia | Grade 1 Creatinine Increase | Grade 2 Creatinite increase | Grade 2 Desquamating Rash | Grade 2 Headache | Grade 2 Hot flashes | Grade 1 Nausea | Grade 3 Pain in extremity | Grade 1 Fever | Grade 1 Vomiting | Grade 1 Musculoskeletal disorder | Grade 2 Urogenital disorder | |
| Zoledronic Acid | 7 | 4 | 1 | 7 | 2 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 1 | 1 |
2 trials available for letrozole and Low Bone Density
| Article | Year |
|---|---|
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density | 2019 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Brea | 2010 |
3 other studies available for letrozole and Low Bone Density
| Article | Year |
|---|---|
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density C | 2016 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |